Labplus
Labplus is a Polish medtech company that offers LabTest Checker, a Class IIa-certified AI medical device providing context-aware interpretation of laboratory test results for diagnostic labs and healthcare providers via B2B WebAPI licensing.
- Company typePrivate
- Founded2018
- HeadquartersWroclaw, Poland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Labplus does
Labplus S.A. is a Wroclaw, Poland-based medtech company that has developed LabTest Checker, a Class IIa certified medical device (under EU MDR 2017/745) that uses artificial intelligence to interpret laboratory test results in the context of each patient's individual clinical profile. The core technology combines numerical lab results with a personalized medical questionnaire covering conditions, medications, symptoms, and risk factors, then generates context-aware health recommendations and flags clinically significant deviations. The system is validated at 97.45% accuracy and 99.42% safety, with clinical study results peer-reviewed in JMIR and extended to 100+ lab parameters in Q1 2026.
The company operates a B2B enterprise licensing model, distributing LabTest Checker exclusively through partnerships with diagnostic laboratories and healthcare providers via WebAPI integration. The integration reportedly takes an average of eight days and requires zero upfront investment from partner labs, with monthly subscription/usage-based billing. Named enterprise customers include Diagnostyka (CEE's largest diagnostic lab network), Synevo (a leading European diagnostic network), Lab-Med, Radomskie Centrum Onkologii, badaj.to, and uPacjenta. Labplus targets primary customer segments of diagnostic laboratories, healthcare providers, and corporate health programs, with the value proposition centered on converting one-time test interactions into ongoing patient relationships and increasing lab LTV.
The company was founded circa 2018-2022 (sources conflict), is headquartered in Wroclaw, Poland, operates with 11-50 employees, and has raised approximately $1.5M (7M PLN) in pre-seed funding led by LT Capital with participation from Movens Capital and a grant from Poland's National Centre for Research and Development. The company is registered as a Polish joint-stock company (Spółka Akcyjna) with ISO 13485 quality certification from TÜV SÜD, GDPR-compliant data processing, and a Medical Advisory Board led by Prof. Grzegorz Mazur.
Labplus firmographics
Firmographics- Name
- Labplus
- Legal name
- Labplus S.A.
- Website
- https://labplus.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Labplus is a Polish medtech company that offers LabTest Checker, a Class IIa-certified AI medical device providing context-aware interpretation of laboratory test results for diagnostic labs and healthcare providers via B2B WebAPI licensing.
- Ownership category
- akta.pro rank
Labplus industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Lab Middleware, Instrument Connectivity & Automation (HLACAMAI)
- akta.pro secondary industry
- Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG)
Keywords
Where Labplus is headquartered
LocationHeadquarters
- HQ city
- Wroclaw
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Labplus business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- LabTest Checker B2B Licensing: Labplus provides its LabTest Checker technology to laboratory networks and healthcare providers through B2B licensing arrangements. The company integrates via WebAPI into partner platforms with no upfront investment required for partners, indicating a subscription or usage-based revenue model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | B2B Enterprise Licensing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Labplus product offering
Product offeringCore offering
Labplus develops LabTest Checker, a certified Class IIa medical device under EU MDR 2017/745 that uses AI to interpret laboratory test results. The system combines numerical lab parameters with a personalized medical questionnaire (conditions, medications, symptoms, risk factors) to deliver context-aware health insights, clinically relevant follow-up test recommendations in 78.3% of cases, and prophylactic screening suggestions. The product is licensed to diagnostic laboratories, hospitals, and corporate health platforms via WebAPI integration with an 8-day average deployment time and zero upfront investment for partners.
Product overview
Labplus offers a single unified product: LabTest Checker, a Class IIa medical device that provides AI-powered interpretation of laboratory test results. The system combines numerical lab data with a personalized patient medical questionnaire to generate context-aware health insights and actionable recommendations. It is designed for integration with laboratory and healthcare provider systems via WebAPI, and serves adult patients (18+) across Poland and international markets.
Differentiator
Problem solved
Functional benefit
Brands
- LabTest Checker: AI-powered laboratory test result interpretation system that provides patients with diagnoses, recommendations, and next-step guidance based on their lab results combined with personalized medical interviews. Certified as a Class IIa medical device under EU MDR 2017/745.
Products and services
- LabTest Checker LabTest Checker is a certified Class IIa medical device (EU MDR 2017/745, Notified Body 2443) that transforms raw laboratory test results into personalized health insights and next-step recommendations for adult patients (18+, except pregnancy). It combines numerical lab results with a personalized medical questionnaire covering conditions, medications, symptoms, and risk factors to deliver context-aware interpretations. Clinically validated with 97.45% accuracy, 99.42% safety, and 99.32% sensitivity for urgent conditions. Delivered to diagnostic laboratories, hospitals, oncology centers, and corporate health platforms via WebAPI integration with an 8-day average deployment time and zero upfront investment for partners.
Quantifiable outcome
- 97.45% accuracy rate (acceptance threshold ≥90%)
- +6 more outcomes
Companies that use Labplus
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Labplus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
Labplus partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Medical University of SilesiacoreClinical validation partner for LabTest Checker. Conducted clinical study that validated the system, with results peer-reviewed and published in JMIR (Journal of Medical Internet Research). Validation extended to 100+ lab parameters in Q1 2026.
- TÜV SÜDminorNotified Body providing ISO 13485 quality system certification for Labplus as a medical device manufacturer.
Scale indicators8 records
Recent moves6 records
Expansion highlights3 records
Labplus competitors and assessment
Company assessmentDirect peers
- Mediktor: Mediktor provides an AI-powered pre-diagnosis and triage engine that evaluates patient symptoms and clinical inputs to suggest likely conditions. Comparable to Labplus because both deploy regulated clinical AI to interpret patient health inputs and route people to the right next step, and both target enterprise healthcare customers.
- Prognos Health: Prognos applies AI to laboratory and claims data to surface clinical insights for providers, payers, and life sciences. Directly comparable because both commercialise AI-driven interpretation of lab data as a paid B2B service to clinical stakeholders.
- Ada Health: Ada Health offers an AI symptom assessment and clinical reasoning platform used by healthcare providers and consumers. Comparable to Labplus because both deliver regulated AI health interpretation that produces patient-facing guidance and next-step recommendations.
Emerging players
- K Health: K Health combines AI-driven intake and lab-result interpretation with telehealth consultations for consumers and enterprise health plans. Comparable because it pairs AI interpretation of clinical inputs with downstream care navigation, similar to Labplus's interpretation-plus-consultation model.
- Dascena: Dascena builds machine-learning models on EHR and lab data to predict patient deterioration and guide earlier interventions. Comparable because both operate in regulated clinical AI and turn lab/EHR data into actionable clinical decisions for providers.
Broad incumbents
- Health Catalyst: Health Catalyst is a healthcare data and analytics platform that ingests lab, clinical, and operational data to drive decision support at hospitals and health systems. Broader incumbent in the same analytical-decision-support category that Labplus targets at the narrower lab-interpretation layer.
- Tempus Labs: Tempus applies AI to clinical and molecular data to support diagnostics and precision medicine across provider and life-science customers. Broader incumbent in clinical AI interpretation; comparable to Labplus because both monetise AI-driven interpretation of diagnostic data in regulated settings.
- Siemens Healthineers: Siemens Healthineers is a major diagnostics and imaging vendor with an installed base of laboratory instruments and growing clinical AI capabilities. Relevant incumbent because it sells into the same diagnostic laboratories that Labplus serves and could natively bundle interpretation features.
- Roche Diagnostics: Roche Diagnostics is one of the world's largest in-vitro diagnostics providers with a global lab services footprint. Comparable as a broad incumbent that controls much of the lab ecosystem Labplus sells into and could potentially bundle or compete with lab interpretation software.
Others
- LabWare: LabWare is a major Laboratory Information Management System (LIMS) vendor used by clinical and analytical labs worldwide. Adjacent because LabWare sits in the same IT stack that Labplus's WebAPI integrates with; potential partner or competitor depending on how LIS vendors evolve their own result-interpretation features.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Labplus social profiles
Digital presenceLabplus compliance and trust
Trust signalCompliance4 records
Labplus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Labplus leadership team
Management profileNumber of profiles
Profiles4 records
Labplus funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Labplus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Labplus
What does Labplus do?
Labplus develops LabTest Checker, a certified Class IIa medical device under EU MDR 2017/745 that uses AI to interpret laboratory test results. The system combines numerical lab parameters with a personalized medical questionnaire (conditions, medications, symptoms, risk factors) to deliver context-aware health insights, clinically relevant follow-up test recommendations in 78.3% of cases, and prophylactic screening suggestions. The product is licensed to diagnostic laboratories, hospitals, and corporate health platforms via WebAPI integration with an 8-day average deployment time and zero upfront investment for partners.
Is Labplus a public or private company?
Labplus is a private company. It is classified as venture growth investor backed and is currently operating.
When was Labplus founded?
Labplus was founded in 2018. It employs 11 to 50 people.
Where is Labplus based?
Labplus is headquartered in Wroclaw, Poland, in the Europe region.
How does Labplus make money?
One revenue line is on record: labTest Checker B2B Licensing.
Who are Labplus's main competitors?
Direct peers on record are Mediktor, Prognos Health and Ada Health. Emerging players are K Health and Dascena. Broad incumbents are Health Catalyst, Tempus Labs, Siemens Healthineers and Roche Diagnostics. LabWare is listed as an others.
Does Labplus have an API?
Yes. Labplus offers a WebAPI integration for partners (labs and healthcare providers) to connect their systems. The integration is described as seamless with minimal effort required. Technical documentation spans 3 pages. Integration typically takes 8 days on average with direct IT specialist support provided.
What industry is Labplus in?
Labplus's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAMAI, Lab Middleware, Instrument Connectivity & Automation, with a secondary code of HLAGAJAG, Lab Automation, Instrument Control & Workflow Orchestration Software. Its NAICS code is 621511 and its SIC code is 8071.